Spots Global Cancer Trial Database for PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
Official Title: A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities
Study ID: NCT01325688
Conditions
Study Description
Brief Summary: This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southderm Pty Ltd, Kogarah, New South Wales, Australia
St George Dermatology, Kogarah, New South Wales, Australia
The Skin Centre, Benowa, Queensland, Australia
Specialist Connect, Woolloongabba, Queensland, Australia
Dermatology Institute of Victoria, South Yarra, Victoria, Australia
St John of God Dermatology, Subiaco, Western Australia, Australia
Burswood Dermatology, Victoria Park, Western Australia, Australia
Contact Details
Name: Jacqueline Morley
Affiliation: Peplin Operations
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
